Nebivolol is a beta-1 receptor blocker used to treat hypertension, heart failure, erectile
dysfunction, vascular disease, and diabetes mellitus. This review investigated the data …

Objective: Nonvasodilatory beta blockers are associated with inferior cardiovascular event
reduction compared with other antihypertensive classes, and there is uncertainty about first …

We compared the antihypertensive activity of DL-and D-nebivolol in patients with essential
hypertension on clinic and 24-h ambulatory blood pressure (BP) and during dynamic …

Combining multiple classes of antihypertensive drugs together is one of the most important
factors for achieving blood pressure control in most hypertensive patients. The benefits of …

Long–term safety of a free–tablet combination of nebivolol and valsartan was assessed in a
Phase III, open–label trial (NCT01415505). Adults with hypertension entered a 4–week …

Nebivolol, a selective β1-lipophilic blocker, achieves blood pressure control by modulating
nitric oxide release in addition to b-blockade. This dual mechanism of action could result in …

Nebivolol is a beta blocker with a unique function which distinguishes it from other beta
blockers. It increases the release of nitric oxide (NO) which produces vasodilatation and …

Purpose The pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of
nebivolol are reviewed. Summary Nebivolol, a third-generation, highly β1-specific β-blocker …

This was a double-blind, randomized, two-center, active-controlled, prospective, parallel
study designed to evaluate the effects of nebivolol at daily doses of 5 mg on lipid and …

Although its clinical use in Europe dates almost 10 years, nebivolol is a β-blocker that has
been only recently introduced in the US market. Like carvedilol, nebivolol belongs to the …